Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol
- VernacularTitle:ADRB1Arg389Gly多态性对比索洛尔疗效影响的Meta分析
- Author:
Tianqi ZHANG
1
;
Ting LI
1
;
Tian ZHANG
1
;
Zinan ZHAO
1
;
Liwei JI
1
Author Information
1. Dept. of Pharmacy，Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine，Chinese Academy of Medical Science/Beijing Key Laboratory of Assessment for Clinical Risk and Individual Application of Drugs，Beijing 100730，China
- Publication Type:Journal Article
- Keywords:
bisoprolol;
β1-adrenergic receptor;
ADRB1 Arg389Gly;
gene polymorphism;
meta-analysis
- From:
China Pharmacy
2024;35(5):601-606
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the effects of ADRB1 Arg389Gly polymorphisms on the efficacy of bisoprolol， thus providing some information for individualized drug therapy. METHODS A systematic search was conducted in PubMed， Embase， Cochrane Library， CBM， CNKI， and Wanfang Data to retrieve and find out all relevant literature about bisoprolol and ADRB1 Arg389Gly polymorphism from the inception to May 2023. The retrieved literature was screened and selected according to the inclusive and exclusive criteria， thereafter quality assessment was conducted. RevMan 5.4 software was utilized to perform the meta- analysis for the outcome index. RESULTS Overall 7 literature with 1 339 cases were included. Among them， 4 studies provided the changes in systolic blood pressure （SBP）， diastolic blood pressure （DBP） （ΔSBP and ΔDBP）； 4 involving the change （ΔLVEF） of left ventricular ejection fraction （LVEF）. Results of the study showed that there was no statistical significance in the improvement of blood pressure between wild-type group （AA） and mutation group （AG+GG） of ADRB1 Arg389Gly treated with bisoprolol {ΔSBP [SMD＝0.17，95%CI （－0.97，1.31）， P＝0.77]， ΔDBP [SMD＝－0.01，95%CI （－0.65，0.62）， P＝0.97]}； there was no statistical significance in the improvement of ΔLVEF [SMD＝－0.61， 95%CI （－2.74，1.53）， P＝0.58] between 2 groups. CONCLUSIONS ADRB1 Arg389Gly gene polymorphism has no significant influence on the improvement of SBP， DBP， and LVEF in cardiovascular patients who use bisoprolol.
